
Eric L. Bolda
Examiner (ID: 16664, Phone: (571)272-8104 , Office: P/3645 )
| Most Active Art Unit | 3645 |
| Art Unit(s) | 3663, 3645 |
| Total Applications | 1609 |
| Issued Applications | 1332 |
| Pending Applications | 112 |
| Abandoned Applications | 196 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18056499
[patent_doc_number] => 20220387585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => ADOPTIVE CELL THERAPY USING SPHERICAL NUCLEIC ACIDS (SNAS)
[patent_app_type] => utility
[patent_app_number] => 17/814211
[patent_app_country] => US
[patent_app_date] => 2022-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10978
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814211
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814211 | ADOPTIVE CELL THERAPY USING SPHERICAL NUCLEIC ACIDS (SNAS) | Jul 20, 2022 | Pending |
Array
(
[id] => 19960299
[patent_doc_number] => 12329771
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-17
[patent_title] => Methods relating to lung cancer
[patent_app_type] => utility
[patent_app_number] => 17/867929
[patent_app_country] => US
[patent_app_date] => 2022-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 10
[patent_no_of_words] => 24681
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17867929
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/867929 | Methods relating to lung cancer | Jul 18, 2022 | Issued |
Array
(
[id] => 19923160
[patent_doc_number] => 12297431
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Modulation of huntingtin expression
[patent_app_type] => utility
[patent_app_number] => 17/813249
[patent_app_country] => US
[patent_app_date] => 2022-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 36649
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 195
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813249
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/813249 | Modulation of huntingtin expression | Jul 17, 2022 | Issued |
Array
(
[id] => 19076699
[patent_doc_number] => 11946050
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Polynucleotide compositions and methods for gene expression regulations
[patent_app_type] => utility
[patent_app_number] => 17/867446
[patent_app_country] => US
[patent_app_date] => 2022-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 21
[patent_no_of_words] => 27978
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17867446
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/867446 | Polynucleotide compositions and methods for gene expression regulations | Jul 17, 2022 | Issued |
Array
(
[id] => 18056234
[patent_doc_number] => 20220387320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA
[patent_app_type] => utility
[patent_app_number] => 17/811808
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811808 | Dry powder composition comprising long-chain RNA | Jul 10, 2022 | Issued |
Array
(
[id] => 18056234
[patent_doc_number] => 20220387320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA
[patent_app_type] => utility
[patent_app_number] => 17/811808
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811808 | Dry powder composition comprising long-chain RNA | Jul 10, 2022 | Issued |
Array
(
[id] => 18056234
[patent_doc_number] => 20220387320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA
[patent_app_type] => utility
[patent_app_number] => 17/811808
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811808 | Dry powder composition comprising long-chain RNA | Jul 10, 2022 | Issued |
Array
(
[id] => 18056234
[patent_doc_number] => 20220387320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA
[patent_app_type] => utility
[patent_app_number] => 17/811808
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811808 | Dry powder composition comprising long-chain RNA | Jul 10, 2022 | Issued |
Array
(
[id] => 20158487
[patent_doc_number] => 12385099
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Circulating microrna signatures for ovarian cancer
[patent_app_type] => utility
[patent_app_number] => 17/810495
[patent_app_country] => US
[patent_app_date] => 2022-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 31
[patent_no_of_words] => 13841
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810495
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/810495 | Circulating microrna signatures for ovarian cancer | Jun 30, 2022 | Issued |
Array
(
[id] => 18384700
[patent_doc_number] => 11655472
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-23
[patent_title] => Antisense nucleic acid that induces skipping of exon 50
[patent_app_type] => utility
[patent_app_number] => 17/847333
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 12192
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847333
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/847333 | Antisense nucleic acid that induces skipping of exon 50 | Jun 22, 2022 | Issued |
Array
(
[id] => 18504854
[patent_doc_number] => 11702659
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
[patent_app_type] => utility
[patent_app_number] => 17/846526
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 38495
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846526
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846526 | Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | Jun 21, 2022 | Issued |
Array
(
[id] => 18268260
[patent_doc_number] => 20230089502
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => PRODUCTS AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/843657
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15935
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843657
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843657 | PRODUCTS AND COMPOSITIONS | Jun 16, 2022 | Abandoned |
Array
(
[id] => 19372944
[patent_doc_number] => 12064483
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => Nucleic acid-polypeptide compositions and methods of inducing exon skipping
[patent_app_type] => utility
[patent_app_number] => 17/843705
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 60
[patent_no_of_words] => 51935
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843705
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843705 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | Jun 16, 2022 | Issued |
Array
(
[id] => 19923161
[patent_doc_number] => 12297432
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
[patent_app_type] => utility
[patent_app_number] => 17/842478
[patent_app_country] => US
[patent_app_date] => 2022-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44305
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842478
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842478 | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity | Jun 15, 2022 | Issued |
Array
(
[id] => 18198490
[patent_doc_number] => 20230052009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => RNA Containing Modified Nucleosides and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/840967
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26747
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17840967
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/840967 | RNA containing modified nucleosides and methods of use thereof | Jun 14, 2022 | Issued |
Array
(
[id] => 18058374
[patent_doc_number] => 20220389460
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
[patent_app_type] => utility
[patent_app_number] => 17/840152
[patent_app_country] => US
[patent_app_date] => 2022-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 101280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17840152
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/840152 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | Jun 13, 2022 | Abandoned |
Array
(
[id] => 17911223
[patent_doc_number] => 20220313618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => PLANT VIRAL NUCLEIC ACID DELIVERY PARTICLES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/837325
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25792
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837325
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/837325 | PLANT VIRAL NUCLEIC ACID DELIVERY PARTICLES AND USES THEREOF | Jun 9, 2022 | Pending |
Array
(
[id] => 17867410
[patent_doc_number] => 20220290146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => COMPOUNDS AND METHODS FOR MODULATING ATXN1
[patent_app_type] => utility
[patent_app_number] => 17/751450
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64700
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751450
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/751450 | Compounds and methods for modulating ATXN1 | May 22, 2022 | Issued |
Array
(
[id] => 18323789
[patent_doc_number] => 20230121917
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => Immunomodulatory RNA
[patent_app_type] => utility
[patent_app_number] => 17/749039
[patent_app_country] => US
[patent_app_date] => 2022-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23421
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749039
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/749039 | Immunomodulatory RNA | May 18, 2022 | Issued |
Array
(
[id] => 19898029
[patent_doc_number] => 12275938
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-15
[patent_title] => Modified RNA agents with reduced off-target effect
[patent_app_type] => utility
[patent_app_number] => 17/743663
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 47
[patent_figures_cnt] => 46
[patent_no_of_words] => 99555
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743663
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/743663 | Modified RNA agents with reduced off-target effect | May 12, 2022 | Issued |